奈玛特韦与莫努匹韦,阿兹夫定对比分析

Comparative analysis of Nematvir, Monupivir and Azivudine

Both Monupivir and Azivudine are drugs that can treat new coronavirus infections, but the three drugs are still different in terms of indications, usage and dosage, side effects, therapeutic effects and recommendation levels. Patients can make a choice based on their own circumstances.

Differences in indications between Nematvir, Monupivir and Azivudine

Nematrevir was developed by Pfizer and is also called Nematvir/ritonavir (Paxlovid). It has been launched in China. It is indicated for the treatment of patients diagnosed with COVID-19 who have mild to moderate symptoms and are accompanied by high-risk factors for progression to severe disease. They are 12 years old and above and weigh at least 40 kilograms. It is developed by Merck in the United States and is also called Monupiravir (already on the market in China). Monupiravir is indicated for confirmed COVID-19 patients aged 18 and above with mild to moderate symptoms and high risk factors for progression to severe disease. Azivudine was developed by domestic real-life biopharmaceuticals and is already on the market. Its indications are adult patients with common COVID-19 who are 18 years old and above.

The difference between Nematvir, Monupivir and Azivudine

Nematvir should be started within 5 days of the onset of symptoms. It can be taken orally before or after meals. Swallow the whole tablet without breaking, chewing or crushing it. The recommended dose is nematvir 300mg (2 tablets) + ritonavir 100mg (1 tablet). Take orally every 12 hours for 5 days. Patients with moderate renal impairment: Nematvir 1 50 mg (1 tablet) + ritonavir 100 mg (1 tablet), taken orally every 12 hours. Patients with severe hepatic impairment: Not recommended.

Monupivir should be started within 5 days of the onset of symptoms. It can be taken orally before or after meals. Swallow the tablet whole without breaking, chewing or crushing it. Take 800mg (four 200mg capsules) orally every 12 hours for 5 days. The safety and effectiveness of administration for more than 5 days have not been determined.

Azivudine should also be taken within 5 days after the onset of symptoms, on an empty stomach. To ensure the dose, the tablet should be swallowed whole and not crushed. Each dose is 5 mg, once a day, and should be continued for 5 days and no more than 14 days. Patients with moderate to severe liver damage should use it with caution.

Differences in side effects of Nematvir, Monupivir and Azivudine

Mainly changes in taste (bitter taste), diarrhea, indigestion, gastroesophageal reflux disease, vomiting, and muscle aches. The main side effects are diarrhea, nausea, dizziness, and headache; the common side effects of Azivudine are mainly fever, dizziness, nausea, and diarrhea.

The difference between the effects of Nematvir, Monupivir and Azivudine

Data given by the U.S. FDA for nematvir is that it reduces the risk of hospitalization and death in high-risk patients with severe disease by 88%. Instead, it reduces the risk of hospitalization and death in high-risk patients with severe disease by 50%; the efficacy data of Azivudine is that 40.43% of clinical symptoms are improved, and the viral load decreases on the fifth day.

The difference between the recommendation levels of Nematvir, Monupivir and Azivudine

Nematvir is the preferred option in the CDC's guidelines for the treatment of adult patients with COVID-19 (non-hospitalized), with a recommendation level of A, and is included in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Ninth Edition)"; Monupivir is an alternative option in the CDC guidelines, with a recommendation level of C, and should only be used when the first-choice treatment is unavailable, infeasible or clinically inappropriate. Azivudine is included in the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Ninth Edition)" and the latest version of the Guangdong Pharmaceutical Association's Clinical Pharmacy Guidelines for Antiviral Treatment of COVID-19. (Note: A=strong, B=medium, C=weak)

Although Nematrevir, Monupivir, and Azivudine can treat COVID-19, it is recommended that patients take the medicine under the guidance of a doctor. Patients who need overseas versions of Nematrevir and Monupivir can obtain them through domestic professional overseas medical service agencies (such as Medical Companion Travel), which are guaranteed to be genuine and affordable. For more details, please consult customer service staff.

Recommended related articles: